BioStock: Stayble’s pathway to phase III and market

Stayble Therapeutics is in phase IIb with the drug candidate STA363 for the treatment of disc-related chronic low back pain. The next step is to initiate a phase III study with one or more partners, and then launch the product on the market. To learn more about the regulatory pathway to this goal, we spoke with Sara Richardson, VP CMC & Regulatory Affairs.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/staybles-pathway-to-phase-iii-and-market/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se